Compare ONMD & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | RVPH |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 35.4M |
| IPO Year | N/A | N/A |
| Metric | ONMD | RVPH |
|---|---|---|
| Price | $0.88 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.14 |
| AVG Volume (30 Days) | 405.4K | ★ 4.8M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $494,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $0.25 |
| 52 Week High | $4.22 | $2.15 |
| Indicator | ONMD | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 39.54 | 33.74 |
| Support Level | $0.86 | $0.29 |
| Resistance Level | $1.02 | $0.37 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 23.57 | 0.00 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's technology has provens the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade, image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols, paving the way for Real World Evidence.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.